Skip to main content

Table 1 Baseline characteristics of clinical and laboratory data of participants

From: Omega-3 intake is associated with attenuated inflammatory response and cardiac remodeling after myocardial infarction

Characteristics

< 1.7 g n = 204

≥1.7 g n = 217

p-value

Daily intake of ω-3 at admission (g)

1.0(0.7)

2.7(1.3)

< 0.001

Daily intake of ω-3 at 3 months (g)

1.1(0.9)

1.9(1.5)

< 0.001

Age, (years)

60 ± 10

58 ± 11

0.256

Gender: female n(%)

52(26)

52(24)

0.717

Diabetes mellitus, n(%)

31(15)

55(25)

0.010

Hypertension, n(%)

113(56)

141(65)

0.044

Previous myocardial infarction, n(%)

21(10)

22(10)

0.957

Previous stroke, n(%)

11(5)

11(5)

0.881

Coronary reperfusion therapy, n(%)

171(84)

194(89)

0.012

Percutaneous coronary intervention (PCI), n(%)

94(46)

100(46)

0.479

Fibrinolytic therapy, n(%)

125(61)

151(70)

0.052

PCI and fibrinolytic therapy, n(%)

53(26)

65(30)

0.190

Current smoking, n(%)

78(38)

83(39)

0.970

Ex smoking, n(%)

59(29)

70(33)

0.440

Drugs previously in use:

Statin, n(%)

13(6)

13(6)

0.861

Calcium channel blocker, n(%)

20(10)

22(10)

0.922

Beta-blocker, n(%)

40(20)

32(14)

0.139

Angiotensin inhibitor drugs (ACEi or ARB), n(%)

66(32)

93(43)

0.026

Aspirin, n(%)

34(17)

33(15)

0.666

HbA1c, (%)

6.0(0.8)

6.1(1.2)

0.830

Glomerular filtration rate, (mL/min)

70(24)

69(25)

0.173

Triglycerides, (mg/dL)

118(90)

147(126)

0.001

LDL-C, (mg/dL)

118 ± 38

121 ± 48

0.538

HDL-C, (mg/dL)

38(13)

36(13)

0.150

Systolic blood pressure, (mmHg)

130(37)

140(40)

0.016

Diastolic blood pressure, (mmHg)

80(30)

85(26)

0.063

Heart rate, (bpm)

75(18)

75(25)

0.415

Time between MI onset and medical care, (minutes)

120(255)

90(182)

0.126

Killip >I, n(%)

20(10)

26(12)

0.470

Peak CK-MB, (UI/L)

161(243)

200(268)

0.070

Troponin, (ng/mL)

2.40(22.36)

1.52(20.16)

0.468

Body Mass Index, (kg/m2)

25.9(5.1)

26.8(5.0)

0.234

Waist circumference, (cm)

Female

95(14)

93(9)

0.164

Male

95(13)

98(12)

0.173